| Document |
Document Title |
|
WO/2000/064923A1 |
A method for separating sterols from neutral substances containing the sterols, the method comprising: a) providing a hydrocarbon fraction containing the neutral substances; b) subjecting the hydrocarbon fraction to a first purification ...
|
|
WO/2000/064924A1 |
A method for separating sterols from neutral substances comprising the sterols, the method comprising: (a) providing a hydrocarbon fraction containing in the neutral substances; (b) optionally washing the hydrocarbon fraction with water;...
|
|
WO/2000/064921A2 |
A universal process for purifying phytosterols from a wood or plant derived source comprises extracting from the source a concentrated extract comprising phytosterols and a hydrocarbon; complexing the extract so formed with a metal salt;...
|
|
WO/2000/064922A1 |
A method for purifying 4-desmethylsterols from neutral substances containing the 4-desmethylsterols and undesired neutral components, the method comprising the step of treating the neutral substances with a solvent mixture comprising met...
|
|
WO/2000/061694A1 |
The present invention provides a method for manufacturing fat-soluble phytosterol or phytostanol ester of unsaturated fatty acid for inhibiting the absorption of cholesterol and foodstuffs containing the same. The method for manufacturin...
|
|
WO/2000/061603A1 |
The invention relates to a method for producing phytosterols from mixtures containing fatty acid esters and methanol by using known crystallization, filtration, washing and drying techniques. The inventive method is characterized in that...
|
|
WO/2000/059513A1 |
Novel sulfur-containing analogs of 1$g(a),25- dihydroxyvitamin D¿3? are provided. These analogs are synthesized in a convergent manner by joining A-ring and C,D ring fragments. Each analog with 1$g(a),3$g(b)-substituent stereochemistry ...
|
|
WO/2000/059629A1 |
A process for producing anion-layered double hydroxide intercalation compounds wherein a metal hydroxide is used as the starting material of a layered double hydroxide (LDH) as the host substance and an anion compound even having a steri...
|
|
WO/2000/059474A1 |
Novel lipid compounds are provided that may be termed 'pro-cationic' in that they are neutral or negatively charged until they are either brought into contact with cellular membranes or are internalized by cells. The lipids have a hydrop...
|
|
WO/2000/059921A1 |
An end product mixture substantially comprising saturated phytosterols is prepared from a raw material mixture of phytosterols derived from tall oil. At least a substantial portion of the raw material mixture consists of unsaturated phyt...
|
|
WO/2000/058338A1 |
Disclosed are compositions and methods for promoting plant growth. The compounds are cyclopropyl-, cyclobutyl- and cyclopentyl-substituted brassinosteroids having high growth promoting ability. They may be used alone or in combination wi...
|
|
WO/2000/056758A1 |
The invention relates to a method for representing compounds of the general formula (1). The invention further relates to the hitherto unknown compounds of general formulas (5, 6 and 7) in the form of intermediate products and to the use...
|
|
WO/2000/056759A1 |
Steroid derivatives useful as the intermediate for preparing vitamin D derivatives such as 1$g(a), 25-dihydroxyvitamin D¿3? and 2$g(b)-(3-hydroxypropoxy)-1$g(a), 25-dihydroxyvitamin D¿3?, i.e., halides of general formula (II) (wherein ...
|
|
WO/2000/056757A1 |
The invention provides compositions comprising formula 1 steroids, e.g., 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. Th...
|
|
WO/2000/054780A2 |
A unit dose formulation comprising 0.25 to 2 mg of a corticosteroid. This small dose can be used to treat rheumatoid arthritis, especially if adapted to release at least 90 % by weight of the corticosteroid, 2 to 8 hours after administra...
|
|
WO/2000/054756A2 |
Compounds and methods for mitigating neurodegeneration, effecting neuroprotection and/or effecting cognition enhancement in a subject are described. Neurological or cognitive conditions are treated by administering to a subject an effect...
|
|
WO/2000/053618A1 |
The invention relates to 22R-hydroxycholesta-8,14-diene derivatives having general formula (I) wherein R¿1? is OR, OSO¿3?H or =NOR; with R being H, (C¿1-6?)alkyl or (C¿1-6?)acyl; each of R¿2? and R¿3? is independently hydrogen or (...
|
|
WO/2000/052142A2 |
The present invention relates to the use of a new principle for improving the viability and pregnancy potential of oocytes and pre-embryos obtained in connection with in vitro fertilisation and pre-embryo transfer treatment. More specifi...
|
|
WO/2000/051618A1 |
The invention relates to (androst-5-en-17$g(b)-yl)alkyl sulfoxides and sulfones having general formula (I), wherein R¿1? is (H, OR), (H, OSO¿3?H) or NOR; with R being H, (C¿1-6?)alkyl or (C¿1-6?)acyl; each of R¿2? and R¿3? is indep...
|
|
WO/2000/048608A1 |
Efficacious preparations for intravenous administration containing ginsenoside Rb¿1? or its salt which are useful as vascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors. These preparations a...
|
|
WO/2000/047649A1 |
The invention relates to novel double metal cyanide (DMC) catalyts for producing polyether polyols by polyaddition of alkylene oxides to starter compounds with active hydrogen atoms. The catalyst contains a) double metal cyanide compound...
|
|
WO/2000/047570A1 |
The invention relates to a method for producing phytosterols by interesterifiying residues from the production of methyl esters with methanol, using an alkaline catalyst, neutralising the catalyst and separating the unreacted alcohol. Th...
|
|
WO/2000/047604A1 |
The present invention relates to pharmaceutically active unsaturated cholestane derivatives, to pharmaceutical compositions comprising them as active substances and to the use of these novel compounds for the preparation of medicaments. ...
|
|
WO/2000/041699A1 |
The present invention relates to the use of estrogens and delta-gonadien-21-0l-3,20-diones in the treatment or prophylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis or f...
|
|
WO/2000/035938A1 |
The invention relates to 22S-hydroxycholesta-8, 14-diene derivatives having general formula (I) wherein R¿1? is OR, OSO¿3?H or = NOR; with R being H, (C¿1-6?) alkyl or (C¿1-6?) acyl; each of R¿2? and R¿3? is independently hydrogen ...
|
|
WO/2000/034305A1 |
Isolation of the sterol component of a sterol-rich fraction of saponified tall oil pitch is disclosed. Sterol isolation is accomplished by deriving from the tall oil pitch a sterolrich fraction in a hydrocarbon (preferably heptane) phase...
|
|
WO/2000/034307A1 |
The invention relates to sterol phosphates of formula (I) in which R?1¿, R¿2? and R?4¿, independent of one another, represent H and/or methyl and R?3¿ represents linear and/or branched alkyl radicals and/or alkenyl radicals with 1 to...
|
|
WO/2000/027867A1 |
Sterols from the solvent-extracted or distilled neutrals of saponified tall oil pitch are disclosed to be isolated and purified by a process of a liquid-liquid extraction where the hydrocarbon extraction stream is washed with an aqueous ...
|
|
WO/2000/024761A1 |
The invention relates to substituted phenyl alkenoyl guanidines, the pharmaceutically acceptable salts thereof, and physiolgically functional derivatives. Compounds of formula (I) are disclosed, wherein the radicals have the meanings thu...
|
|
WO/2000/023141A1 |
This invention is an electrical stimulation of the vomeronasal organ (VNO) in humans to affect hypothalamic activity to influence autonomic function, to regulate hormone levels, particularly for contraception, and treatment of diseases i...
|
|
WO/2000/023138A1 |
Occlusion of the vomeronasal organ (VNO) in humans is a method for affecting hypothalamic activity, and may be used for regulating hormone levels, influencing autonomic function, and decreasing the risk of spontaneous miscarriage. VNO (1...
|
|
WO/2000/020437A1 |
The invention relates to substituted propanolamine derivatives and their pharmaceutically acceptable salts and physiologically functional derivatives. The invention relates to compounds of formula (I), wherein the radicals have the defin...
|
|
WO/2000/015652A1 |
A method is set forth for separating a sterol or sterol ester from crude tall oil comprising fractionating the crude tall oil into a residue fraction and a volatile fraction, wherein the temperature of the residue fraction does not excee...
|
|
WO/2000/012533A1 |
Isolation of the sterol component of the neutrals fraction of saponified tall oil pitch is disclosed. Sterol isolation is accomplished by a liquid-liquid extraction from the tall oil pitch-derived neutrals, resulting in a hydrocarbon (pr...
|
|
WO/2000/009535A1 |
Isolation of the sterol component of the neutrals fraction of saponified tall oil pitch is disclosed. To the extracted neutrals, in a hydrocarbon (preferably heptane) phase, are added small amounts of water and an alcohol solvent, prefer...
|
|
WO/2000/004038A1 |
Sterols from the neutrals fraction of tall oil pitch are disclosed to be isolated and purified by a process of a liquid-liquid extraction where the hydrocarbon extraction stream is washed with an aqueous methanol solution to remove metha...
|
|
WO/2000/004039A1 |
Sterols from the neutrals fraction of tall oil pitch are disclosed to be isolated and purified by a process of a liquid-liquid extraction where the hydrocarbon extraction stream is washed with an aqueous methanol solution to remove metha...
|
|
WO/1999/067273A1 |
Certain novel sterol derivatives having no hydroxy group in the 3 position can be used to regulate the meiosis in oocytes and in male germ cells.
|
|
WO/1999/065462A2 |
Cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride (Cl?-¿) channel regulated by phosphorylation and intracellular nucleotides. CFTR is the major Cl?-¿ transport pathway in airway epithelial cells. The abnormal tra...
|
|
WO/1999/063841A1 |
A composition suitable for incorporation into foods, beverages, pharmaceuticals, nutraceuticals and the like comprises one or more phytosterols, phytostanols or mixtures of both, treated to enhance the solubility and dispersability thereof.
|
|
WO/1999/058549A1 |
Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells.
|
|
WO/1999/056558A1 |
This invention relates to phytosterols and phytostanols, in particular to fatty acid esters of phytosterols and phytostanols with a specified fatty acid composition. The invention further relates to methods for preparation of the phytost...
|
|
WO/1999/052863A1 |
Vitamin D derivatives represented by general formula (I), intermediate compounds in the synthesis thereof, and medicinal compositions containing these vitamin D derivatives as the active ingredient wherein A represents linear or branched...
|
|
WO/1999/052930A1 |
The invention relates to a new method comprising different ways of producing compounds of formula (1). The invention further relates to the hitherto unknown compounds of formulas (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13),...
|
|
WO/1999/052932A1 |
The present invention relates to bile acid or bile salt fatty acid conjugates (hereinafter called 'BAFAC'), to their use in dissolving cholesterol gallstones in bile, preventing their occurrence or recurrence, to their use in reducing or...
|
|
WO/1999/048907A1 |
The invention relates to a method for producing stanols. Stanols are hydrogenated in the presence of palladium catalysts in an organic solution. Alcohol, paraffin carbohydrates and mixtures of alcohol and carbohydrates can be used as sol...
|
|
WO/1999/047485A1 |
A procedure for oxidizing organic compounds having allylic hydrogen atom(s) involving the steps of reactively contacting the organic compound with a combination of an N-hydroxy dicarboxylic acid imide and a chromium-containing oxidant. T...
|
|
WO/1999/045931A1 |
The use of epiallopregnanolone (3$g(b)-hydroxy-5$g(a)-pregnan-20-one) for the treatment of $i(inter alia) steroid induced mood disorders and CNS disorders is disclosed. Further, the use of epiallopregnanolone for the manufacture of pharm...
|
|
WO/1999/046279A2 |
Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17$g(b)-hydroxy...
|
|
WO/1999/046280A1 |
The invention concerns compounds of formula (I) wherein: R1 represents a C1-C31 hydrocarbon radical, in particular an alkyl radical, linear or branched, saturated or unsaturated; OR2 represents a cholesteryl radical; said compounds being...
|
